Screener
Syndax Pharmaceuticals SNDX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(42,673) | $(84,846) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 4 | — |
| Accretion of investments | (862) | (3,599) |
| Non-cash operating lease expense | 130 | 221 |
| Stock-based compensation | 12,054 | 10,380 |
| Amortization of debt issuance costs | 56 | 112 |
| Changes in operating assets and liabilities: |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Syndax Pharmaceuticals (SNDX) reported accretion (amortization) of discounts and premiums, investments of $862K in Q1 2026.
- How has Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments decreased by 76.0% year-over-year, from $3.6M to $862K.
- What is the long-term trend for Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments has grown at a 102.1% compound annual growth rate (CAGR), from -$644K to $10.75M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This reflects the periodic adjustment to the carrying value of investment securities to account for the difference between the purchase price and the face value. It represents the non-cash impact of interest income recognition on the company's investment portfolio.
Ask your AI about Syndax Pharmaceuticals's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude